JCR Pharmaceuticals Beheer

Beheer criteriumcontroles 2/4

De CEO JCR Pharmaceuticals is Shin Ashida, benoemd in Jun2005, heeft een ambtstermijn van 19.42 jaar. bezit rechtstreeks 0.008% van de aandelen van het bedrijf, ter waarde ¥ 7.06M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 6.4 jaar en 4.8 jaar.

Belangrijke informatie

Shin Ashida

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	19.4yrs
Eigendom CEO	0.008%
Management gemiddelde ambtstermijn	6.4yrs
Gemiddelde ambtstermijn bestuur	4.8yrs

Recente managementupdates

Recent updates

JCR Pharmaceuticals (TSE:4552) Is Paying Out A Dividend Of ¥10.00

Sep 06

What JCR Pharmaceuticals Co., Ltd.'s (TSE:4552) 32% Share Price Gain Is Not Telling You

Sep 04

JCR Pharmaceuticals (TSE:4552) Has Affirmed Its Dividend Of ¥10.00

Aug 23

JCR Pharmaceuticals (TSE:4552) Is Due To Pay A Dividend Of ¥10.00

Aug 09

Earnings Miss: JCR Pharmaceuticals Co., Ltd. Missed EPS By 90% And Analysts Are Revising Their Forecasts

Aug 03

JCR Pharmaceuticals (TSE:4552) Will Pay A Dividend Of ¥10.00

Jul 26

JCR Pharmaceuticals (TSE:4552) Is Paying Out A Dividend Of ¥10.00

Jul 12

JCR Pharmaceuticals Co., Ltd. (TSE:4552) Shares May Have Slumped 28% But Getting In Cheap Is Still Unlikely

May 22

JCR Pharmaceuticals (TSE:4552) Is Due To Pay A Dividend Of ¥10.00

Mar 18

JCR Pharmaceuticals (TSE:4552) Has Affirmed Its Dividend Of ¥10.00

Feb 29

CEO

Shin Ashida (81 yo)

19.4yrs

Tenure

Mr. Shin Ashida has been the Chairman of JCR Pharmaceuticals Co., Ltd. since July 1995 and its Chief Executive Officer since June 2005. Mr. Ashida has been the President and Chief Operating Officer of JCR...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Shin Ashida	Chairman	19.4yrs	geen gegevens	0.0083% ¥ 7.1m
Yoshihiro Ota	Director of Accounting Department & Corporate Strategy Department (Finance)	no data	geen gegevens	geen gegevens
Yutaka Honda	Sr. Exec. Offi. of Admin.	8.4yrs	geen gegevens	geen gegevens
Hiroyuki Fukuya	Director of Legal Affairs Department - Administration Division	no data	geen gegevens	geen gegevens
Toru Ashida	Director	4.6yrs	geen gegevens	0.21% ¥ 178.1m
Ryutaro Makino	Director of Marketing Dept. & Group Manager of Product Planning - Marketing Dept. for Sales Div.	4.1yrs	geen gegevens	geen gegevens
Katsuya Nishino	Executive Vice President	14.3yrs	geen gegevens	geen gegevens
Hiroshi Yoshimoto	Senior Advisor	13.5yrs	geen gegevens	geen gegevens
Takayo Egawa	Senior Executive Officer & Manager of International Affairs Office	no data	geen gegevens	geen gegevens
Hiroyuki Sonoda	Senior Managing Executive Officer of Research	6.4yrs	geen gegevens	0.0019% ¥ 1.6m
Junichi Ando	Managing Executive Officer of Production & Executive Director of Production Division	3.4yrs	geen gegevens	geen gegevens
Yoshio Hiyama	Director	3.4yrs	geen gegevens	0.0021% ¥ 1.8m

6.4yrs

Gemiddelde duur

66yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 4552 is doorgewinterd en ervaren (gemiddelde ambtstermijn van 6.4 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Shin Ashida	Chairman	19.4yrs	geen gegevens	0.0083% ¥ 7.1m
Toru Ashida	Director	no data	geen gegevens	0.21% ¥ 178.1m
Hiroyuki Sonoda	Senior Managing Executive Officer of Research	4.8yrs	geen gegevens	0.0019% ¥ 1.6m
Yoshio Hiyama	Director	3.4yrs	geen gegevens	0.0021% ¥ 1.8m
Andrea Spezzi	Director & Managing Executive Officer of Development Division	less than a year	geen gegevens	geen gegevens
Marc Dunoyer	Independent Outside Director	1.4yrs	geen gegevens	geen gegevens
Kazuhiko Yamada	Outside Audit & Supervisory Board Member	18.4yrs	geen gegevens	0.010% ¥ 8.6m
Philippe Fauchet	Independent Outside Director	2.4yrs	geen gegevens	geen gegevens
Toshihide Yoda	Independent Outside Director	6.4yrs	geen gegevens	geen gegevens
Yutaka Atomi	Independent Outside Director	2.4yrs	geen gegevens	geen gegevens
Takashi Suetsuna	Independent Outside Director	7.4yrs	geen gegevens	geen gegevens
Yuko Hayashi	Independent Outside Director	6.4yrs	geen gegevens	geen gegevens

4.8yrs

Gemiddelde duur

65.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 4552 wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.8 jaar).

JCR Pharmaceuticals Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

JCR Pharmaceuticals Co., Ltd., Annual General Meeting, Jun 26, 2024

JCR Pharmaceuticals Co., Ltd. Announces Organizational and Personnel Changes

Jcr Pharmaceuticals Co., Ltd. Announces Executive Changes

JCR Pharmaceuticals Co., Ltd. Appoints Yoh Ito as Senior Corporate Officer

JCR Pharmaceuticals Co., Ltd. Announces Executive Changes

JCR Pharmaceuticals Co., Ltd. Appoints Pascal Yoshida as Senior Director, Head of Medical Affairs Unit

Recent updates

Second quarter 2025 earnings: EPS and revenues miss analyst expectations

JCR Initiates First Dosing in Phase I Clinical Trial of JR-441 for Mucopolysaccharidosis Type IIIA

JCR Pharmaceuticals Co., Ltd. Announces Interim Dividend

JCR Pharmaceuticals Co., Ltd. Presents Preclinical Gene Therapy Research at the European Society of Gene and Cell Therapy 31st Annual Congress

Upcoming dividend of JP¥10.00 per share

JCR Pharmaceuticals (TSE:4552) Is Paying Out A Dividend Of ¥10.00

What JCR Pharmaceuticals Co., Ltd.'s (TSE:4552) 32% Share Price Gain Is Not Telling You

JCR Pharmaceuticals Co., Ltd. to Report Q2, 2025 Results on Oct 30, 2024

JCR Pharmaceuticals (TSE:4552) Has Affirmed Its Dividend Of ¥10.00

JCR Pharmaceuticals (TSE:4552) Is Due To Pay A Dividend Of ¥10.00

Investor sentiment deteriorates as stock falls 17%

Earnings Miss: JCR Pharmaceuticals Co., Ltd. Missed EPS By 90% And Analysts Are Revising Their Forecasts

First quarter 2025 earnings: EPS and revenues miss analyst expectations

JCR Pharmaceuticals Co., Ltd Announces Discontinuation of TEMCELL HS Inj. Expanded Indication Development for Neonatal Hypoxic Ischemic Encephalopathy

JCR Pharmaceuticals (TSE:4552) Will Pay A Dividend Of ¥10.00

JCR Pharmaceuticals (TSE:4552) Is Paying Out A Dividend Of ¥10.00

Final dividend of JP¥10.00 announced

MEDIPAL Holdings Corporation and JCR Pharmaceuticals Co., Ltd. Announce Completion of Clinical Trial Notification Process in Japan for Phase I/II Study of JR-446 for Mucopolysaccharidosis Type IIIB

Consensus EPS estimates fall by 17%

JCR Pharmaceuticals Co., Ltd. to Report Q1, 2025 Results on Jul 30, 2024

Price target decreased by 10% to JP¥1,314

JCR Pharmaceuticals Co., Ltd. (TSE:4552) Shares May Have Slumped 28% But Getting In Cheap Is Still Unlikely

Investor sentiment deteriorates as stock falls 22%

Full year 2024 earnings: EPS and revenues miss analyst expectations

JCR Pharmaceuticals Co., Ltd., Annual General Meeting, Jun 26, 2024

JCR Pharmaceuticals Co., Ltd. Announces Dividend for the Year Ended March 31, 2024, Payable on June 27, 2024

Upcoming dividend of JP¥10.00 per share

JCR Pharmaceuticals Co., Ltd. Announces Achievement of Milestone Using J-Brain Cargo Technology for Neurodegenerative Disease in Research Collaboration with Alexion

JCR Pharmaceuticals (TSE:4552) Is Due To Pay A Dividend Of ¥10.00

JCR Pharmaceuticals Co., Ltd.(TSE:4552) dropped from FTSE All-World Index (USD)

JCR Pharmaceuticals Co., Ltd. to Report Fiscal Year 2024 Results on May 10, 2024

JCR Pharmaceuticals (TSE:4552) Has Affirmed Its Dividend Of ¥10.00

JCR Pharmaceuticals Co., Ltd. Announces Organizational and Personnel Changes

Now 22% overvalued

JCR Pharmaceuticals Co., Ltd. Presents Clinical Data on J-Brain Cargo®? to Deliver Medicines Across the Blood-Brain Barrier

JCR Pharmaceuticals Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024

Price target decreased by 10% to JP¥1,657

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

JCR Pharmaceuticals Co., Ltd. to Report Q3, 2024 Results on Jan 26, 2024

New major risk - Share price stability

JCR Pharmaceuticals Co., Ltd. Announces First Patient Dosed in a Global Phase I/II Clinical Trial of JR-441 for the Treatment of MPS IIIA

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

JCR Pharmaceuticals Co., Ltd. Declares Interim Dividend for the Fiscal Year Ending March 31, 2024, Payable on December 8, 2023; Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

JCR Pharmaceuticals Co., Ltd. Announces 52-Week Interim Data from its Global Phase I/II Study of JR-171 in Individuals with Mucopolysaccharidosis Type I (MPS I)

Upcoming dividend of JP¥10.00 per share at 1.5% yield

Investor sentiment improves as stock rises 18%

PHC IVD and JCR Announce GROWJECTOR® Duo

JCR Pharmaceuticals Co., Ltd. to Report Q2, 2024 Results on Oct 25, 2023

JCR Pharmaceuticals Co., Ltd. Provides Consolidated Earnings Guidance for the Full Year Ending March 31, 2024

Consensus EPS estimates increase by 13%

First quarter 2024 earnings released: EPS: JP¥12.90 (vs JP¥11.05 in 1Q 2023)

Price target decreased by 7.4% to JP¥1,859

JCR Receives Approval to Start Global Phase I/II Clinical Trial for JR-441 for the Treatment of Mucopolysaccharidosis Type III A (MPS IIIA)

Jcr Pharmaceuticals Co., Ltd. Announces Executive Changes

JCR Pharmaceuticals Co., Ltd. Receives an Approval for Expanded Indication of Growject®? in Short Stature Due to SHOX-Deficiency

Full year 2023 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates increase by 20%

JCR Pharmaceuticals Co., Ltd. Provides Consolidated Earnings Guidance for the Full Year Ending March 31, 2024

JCR Pharmaceuticals Co., Ltd. to Report Q1, 2024 Results on Jul 26, 2023

Consensus EPS estimates fall by 24%

Full year 2023 earnings: EPS and revenues miss analyst expectations

JCR Pharmaceuticals Co., Ltd. Announces Dividend for the Year Ended March 31, 2023, Payable on June 22, 2023

Investor sentiment deteriorates as stock falls 18%

Now 21% undervalued after recent price drop

Consensus revenue estimates fall by 17%

Upcoming dividend of JP¥10.00 per share at 1.3% yield

JCR Pharmaceuticals Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023